CD44 and lung adenocarcinoma: <b>Conclusions:</b> These findings delineate a regulatory model in which lung adenocarcinoma cells directly stimulate NETosis through the NPM1-TNFAIP6-CD44-SPP1 axis, suggesting that therapeutic targeting of this pathway may attenuate tumor progression.